HANSABIOMED LIFE SCIENCES OU

Their core work

HansaBioMed Life Sciences is an Estonian biotech SME specializing in extracellular vesicle (EV) and exosome isolation, characterization, and manufacturing technologies. They develop tools and reagents for capturing, separating, and detecting biological nanoparticles — including immunocapture methods, magnetic nanoparticle-based isolation, and surface-functionalized platforms. Their work spans from diagnostic applications (liquid biopsy, cancer biomarkers) to therapeutic uses (cardiac repair, cell-free therapy), positioning them as a key enabling technology provider in the rapidly growing EV field.

What they specialise in

How they've shifted over time

In their early H2020 period (2017-2018), HansaBioMed focused on analytical and detection capabilities — building chip-based systems for exosome detection using interferometry, optical biosensing, and studying EVs as biomarkers for cancer and autoimmunity. By 2020-2024, their focus shifted decisively toward manufacturing, therapeutic applications, and scale-up — working on EV foundries, peptide-based capture systems for scalable production, cardiac repair, and organotropic delivery. This mirrors the broader EV field's maturation from "can we detect them?" to "can we make and use them at scale?"

HansaBioMed is moving from analytical tools toward scalable EV production and therapeutic applications, making them an increasingly relevant partner for clinical translation projects.

How they like to work

HansaBioMed operates exclusively as a consortium participant, never as coordinator, which is typical for a specialist SME contributing specific technical capabilities to larger research efforts. With 32 unique partners across 15 countries from just 5 projects, they build broad European networks rather than sticking to a fixed set of collaborators. This suggests they are a sought-after niche provider whose EV expertise complements diverse research teams.

Broad European network with 32 unique partners spanning 15 countries from 5 projects, indicating high demand for their specialized EV expertise across diverse consortia. As an Estonian SME, they punch well above their geographic weight in pan-European collaboration.

What sets them apart

HansaBioMed occupies a rare niche as a commercial SME with deep, demonstrated expertise in extracellular vesicle isolation and characterization — a field dominated by academic groups. Their progression from detection tools to manufacturing scale-up means they bridge the gap between lab-scale EV research and industrial production. For consortium builders, they bring both commercial perspective and hands-on EV processing capability that most academic partners cannot offer.

Highlights from their portfolio

• evFOUNDRY
  Largest single grant (EUR 418,000) and directly addresses the industrialization challenge of building an 'Extracellular Vesicle Foundry' for scalable EV production.
• MARVEL
  Bridges therapeutic application (cardiac repair, bladder cancer liquid biopsy) with scalable manufacturing, representing their most translational project.
• INDEX
  Earliest project showcasing their core competence in integrated nanoparticle isolation and on-chip exosome analysis combining multiple detection modalities.